136 related articles for article (PubMed ID: 24326841)
1. Prognostic role of neutrophil-to-lymphocyte ratio in advanced pancreatic ductal adenocarcinoma: impact of baseline fluctuation and changes during chemotherapy.
Teo M; Mohd Sharial MS; McDonnell F; Conlon KC; Ridgway PF; McDermott RS
Tumori; 2013; 99(4):516-22. PubMed ID: 24326841
[TBL] [Abstract][Full Text] [Related]
2. Neutrophil/lymphocyte ratio helps select metastatic pancreatic cancer patients benefitting from oxaliplatin.
Formica V; Morelli C; Ferroni P; Nardecchia A; Tesauro M; Pellicori S; Cereda V; Russo A; Riondino S; Guadagni F; Roselli M
Cancer Biomark; 2016 Sep; 17(3):335-345. PubMed ID: 27434293
[TBL] [Abstract][Full Text] [Related]
3. Significance of baseline and change in neutrophil-to-lymphocyte ratio in predicting prognosis: a retrospective analysis in advanced pancreatic ductal adenocarcinoma.
Chen Y; Yan H; Wang Y; Shi Y; Dai G
Sci Rep; 2017 Apr; 7(1):753. PubMed ID: 28392554
[TBL] [Abstract][Full Text] [Related]
4. Neutrophil to lymphocyte ratio, not platelet to lymphocyte or lymphocyte to monocyte ratio, is predictive of patient survival after resection of early-stage pancreatic ductal adenocarcinoma.
Pointer DT; Roife D; Powers BD; Murimwa G; Elessawy S; Thompson ZJ; Schell MJ; Hodul PJ; Pimiento JM; Fleming JB; Malafa MP
BMC Cancer; 2020 Aug; 20(1):750. PubMed ID: 32782024
[TBL] [Abstract][Full Text] [Related]
5. Neutrophil-to-lymphocyte ratio for predicting palliative chemotherapy outcomes in advanced pancreatic cancer patients.
Xue P; Kanai M; Mori Y; Nishimura T; Uza N; Kodama Y; Kawaguchi Y; Takaori K; Matsumoto S; Uemoto S; Chiba T
Cancer Med; 2014 Apr; 3(2):406-15. PubMed ID: 24519894
[TBL] [Abstract][Full Text] [Related]
6. The relation between inflammation-based parameters and survival in metastatic pancreatic cancer.
Turker S; Cilbir E; Guven DC; Karacin C; Yalcin S
J Cancer Res Ther; 2021; 17(2):510-515. PubMed ID: 34121700
[TBL] [Abstract][Full Text] [Related]
7. Time to CA19-9 nadir: a clue for defining optimal treatment duration in patients with resectable pancreatic ductal adenocarcinoma.
Reni M; Peretti U; Zanon S; Macchini M; Balzano G; Mazza E; Tamburrino D; Orsi G; Arcidiacono PG; Falconi M; Gianni L
Cancer Chemother Pharmacol; 2020 Apr; 85(4):641-650. PubMed ID: 32157412
[TBL] [Abstract][Full Text] [Related]
8. Validation of the pretreatment neutrophil-lymphocyte ratio as a predictor of overall survival in a cohort of patients with pancreatic ductal adenocarcinoma.
Ben Q; An W; Wang L; Wang W; Yu L; Yuan Y
Pancreas; 2015 Apr; 44(3):471-7. PubMed ID: 25423560
[TBL] [Abstract][Full Text] [Related]
9. Preoperative independent prognostic factors in patients with borderline resectable pancreatic ductal adenocarcinoma following curative resection: the neutrophil-lymphocyte and platelet-lymphocyte ratios.
Asari S; Matsumoto I; Toyama H; Shinzeki M; Goto T; Ishida J; Ajiki T; Fukumoto T; Ku Y
Surg Today; 2016 May; 46(5):583-92. PubMed ID: 26108488
[TBL] [Abstract][Full Text] [Related]
10. Increased neutrophil-to-lymphocyte ratio after neoadjuvant therapy is associated with worse survival after resection of borderline resectable pancreatic ductal adenocarcinoma.
Glazer ES; Rashid OM; Pimiento JM; Hodul PJ; Malafa MP
Surgery; 2016 Nov; 160(5):1288-1293. PubMed ID: 27450715
[TBL] [Abstract][Full Text] [Related]
11. The Prognostic Value of Preoperative Neutrophil-to-Lymphocyte Ratio in Resected Patients with Pancreatic Adenocarcinoma.
Fang LP; Xu XY; Ji Y; Huang PW
World J Surg; 2018 Nov; 42(11):3736-3745. PubMed ID: 30014292
[TBL] [Abstract][Full Text] [Related]
12. Low lymphocyte monocyte ratio after neoadjuvant therapy predicts poor survival after pancreatectomy in patients with borderline resectable pancreatic cancer.
Kawai M; Hirono S; Okada KI; Miyazawa M; Shimizu A; Kitahata Y; Kobayashi R; Ueno M; Hayami S; Tanioka K; Yamaue H
Surgery; 2019 Jun; 165(6):1151-1160. PubMed ID: 30765142
[TBL] [Abstract][Full Text] [Related]
13. Prognostic Impact of the Neutrophil-to-Lymphocyte Ratio in Borderline Resectable Pancreatic Ductal Adenocarcinoma Treated with Neoadjuvant Chemoradiotherapy Followed by Surgical Resection.
Kubo H; Murakami T; Matsuyama R; Yabushita Y; Tsuchiya N; Sawada Y; Homma Y; Kumamoto T; Endo I
World J Surg; 2019 Dec; 43(12):3153-3160. PubMed ID: 31549202
[TBL] [Abstract][Full Text] [Related]
14. Serum CA 19-9 response to neoadjuvant therapy is associated with outcome in pancreatic adenocarcinoma.
Boone BA; Steve J; Zenati MS; Hogg ME; Singhi AD; Bartlett DL; Zureikat AH; Bahary N; Zeh HJ
Ann Surg Oncol; 2014 Dec; 21(13):4351-8. PubMed ID: 25092157
[TBL] [Abstract][Full Text] [Related]
15. Prognostic value of neutrophil-lymphocyte ratio and level of C-reactive protein in a large cohort of pancreatic cancer patients: a retrospective study in a single institute in Japan.
Inoue D; Ozaka M; Matsuyama M; Yamada I; Takano K; Saiura A; Ishii H
Jpn J Clin Oncol; 2015 Jan; 45(1):61-6. PubMed ID: 25341546
[TBL] [Abstract][Full Text] [Related]
16. Preoperative serum C-reactive protein levels and post-operative lymph node ratio are important predictors of survival after pancreaticoduodenectomy for pancreatic ductal adenocarcinoma.
Sanjay P; de Figueiredo RS; Leaver H; Ogston S; Kulli C; Polignano FM; Tait IS
JOP; 2012 Mar; 13(2):199-204. PubMed ID: 22406601
[TBL] [Abstract][Full Text] [Related]
17. Combined systemic inflammation score (SIS) correlates with prognosis in patients with advanced pancreatic cancer receiving palliative chemotherapy.
Markus M; Abendroth A; Noureddine R; Paul A; Breitenbuecher S; Virchow I; Schmid KW; Markus P; Schumacher B; Wiesweg M; Wendling J; Mende B; Siveke JT; Schuler M; Kasper S
J Cancer Res Clin Oncol; 2021 Feb; 147(2):579-591. PubMed ID: 32839836
[TBL] [Abstract][Full Text] [Related]
18. Pretherapy neutrophil to lymphocyte ratio and platelet to lymphocyte ratio do not predict survival in resectable pancreatic cancer.
Chawla A; Huang TL; Ibrahim AM; Hardacre JM; Siegel C; Ammori JB
HPB (Oxford); 2018 May; 20(5):398-404. PubMed ID: 29221789
[TBL] [Abstract][Full Text] [Related]
19. Neutrophil-lymphocyte ratio (NLR) was associated with prognosis and immunomodulatory in patients with pancreatic ductal adenocarcinoma (PDAC).
Xiang ZJ; Hu T; Wang Y; Wang H; Xu L; Cui N
Biosci Rep; 2020 Jun; 40(6):. PubMed ID: 32510138
[TBL] [Abstract][Full Text] [Related]
20. The Neutrophil/Lymphocyte Ratio at Diagnosis Is Significantly Associated with Survival in Metastatic Pancreatic Cancer Patients.
Piciucchi M; Stigliano S; Archibugi L; Zerboni G; Signoretti M; Barucca V; Valente R; Fave GD; Capurso G
Int J Mol Sci; 2017 Mar; 18(4):. PubMed ID: 28353661
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
